Making Strides in Small Cell Lung Cancer: An Update on Targeted Therapies | Transcript | Lung Cancer | Patient Power


Making Strides in Small Cell Lung Cancer: An Update on Targeted Therapies

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

It's kind of interesting. Small cell, you would think, since it's prevalent largely in smokers, people with smoking exposure, could be very—a lot of mutations being present.  We know that total mutation burden is a nice predictor of benefit in non-small cell lung cancer, so we think that would—might play out here. There is PD-L1 expression in small cell, but it's not as intense.  And there is some separation by PD-L1 score of benefit for immune checkpoint therapy in small cell, but the responses in general are less than they have been in non?small cell.  So we're going to need more, more homework to figure this one out, but I think we're taking some steps in the right direction.   

And as Dr. Kim pointed out, roba?T is a targeted therapy, maybe one of the first targeted therapies we've had in small cell that attacks antigen present on a lot of small cell called B-L-L-3, and there are other therapies being developed against that BLL3, because we know that's an important marker.  So I hope we will see agents that are truly targeted therapies in small cell in the next few years.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on August 17, 2018